BelarusTuberculosis profile
Population  2015 9.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.45 (0.42–0.49) 4.8 (4.5–5.1)
Mortality (HIV+TB only) 0.072 (0.021–0.15) 0.76 (0.22–1.6)
Incidence  (includes HIV+TB) 5.2 (3.9–6.8) 55 (41–71)
Incidence (HIV+TB only) 0.3 (0.2–0.44) 3.2 (2.1–4.6)
Incidence (MDR/RR-TB)** 3.5 (2.8–4.2) 37 (29–44)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.11 (0.021–0.2) 1.3 (0.48–2.2) 1.4 (0.5–2.4)
Males 0.22 (0.14–0.3) 3.6 (2.7–4.5) 3.8 (2.8–4.8)
Total 0.33 (0.23–0.43) 4.9 (4.1–5.7) 5.2 (3.9–6.8)
TB case notifications, 2015  
Total cases notified 4 177
Total new and relapse 3 765
          - % tested with rapid diagnostics at time of diagnosis 72%
          - % with known HIV status 99%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 78%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 72% (56–97)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.1 (0.08–0.14)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 206 6%
          - on antiretroviral therapy 174 84%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 800
(1 700–1 800)
Estimated % of TB cases with MDR/RR-TB 37% (35–39) 69% (66–72)  
% notified tested for rifampicin resistance 69% 65% 2 825
MDR/RR-TB cases tested for resistance to second-line drugs   1 281
Laboratory-confirmed cases MDR/RR-TB: 1 340, XDR-TB: 460
Patients started on treatment **** MDR/RR-TB: 1 949, XDR-TB: 508
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 88% 2 706
Previously treated cases, excluding relapse, registered in 2014 73% 249
HIV-positive TB cases, all types, registered in 2014 74% 135
MDR/RR-TB cases started on second-line treatment in 2013 54% 2 136
XDR-TB cases started on second-line treatment in 2013 38% 60
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 15
Funding source: 57% domestic, 15% international, 28% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data